Success Metrics

Clinical Success Rate

66.7%

Based on 4 completed trials

Completion Rate

67%(4/6)

Active Trials

1(13%)

Results Posted

75%(3 trials)

Terminated

2(25%)

Phase Distribution

Ph phase_1

63%

Ph phase_2

38%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

5(62.5%)

Phase 2Efficacy & side effects

3(37.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(4)

Terminated(3)

Detailed Status

Completed4

Terminated2

Active, not recruiting1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 2

Trials by Phase

Phase 15 (62.5%)

Phase 23 (37.5%)

Trials by Status

active_not_recruiting113%

completed450%

terminated225%

withdrawn113%

Recent Activity

1 active trials

Showing 5 of 8

completedphase_1

Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)

NCT04926285

active_not_recruitingphase_1

Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

NCT03564873

completedphase_2

Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

NCT02159872

terminatedphase_2

Omacetaxine for Consolidation and Maintenance

NCT01873495

completedphase_2

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

NCT01272245

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT04926285Phase 1

Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)

Completed

NCT03564873Phase 1

Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

Active Not Recruiting

NCT02159872Phase 2

Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

Completed

NCT01873495Phase 2

Omacetaxine for Consolidation and Maintenance

Terminated

NCT01272245Phase 2

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Completed

NCT02141477Phase 1

Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Terminated

NCT02835794Phase 1

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

Withdrawn

NCT00675350Phase 1

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8